MeiraGTx Holdings plc (MGTX)
Automate Your Wheel Strategy on MGTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MGTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MGTX
- Rev/Share 0.4123
- Book/Share 0.4188
- PB 12.7984
- Debt/Equity 0.0996
- CurrentRatio 1.5254
- ROIC -0.8915
- MktCap 430758544.0
- FreeCF/Share -1.3864
- PFCF -3.9314
- PE -2.5316
- Debt/Assets 0.0147
- DivYield 0
- ROE -2.4189
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.77 per share a year ago.
Read More
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the treatment …
Read More
MeiraGTx Holdings: Gaining Regulatory Focus
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Positive
MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson's Disease, and xerostomia, with multiple assets in advanced clinical stages showing promising efficacy and safety data. MGTX uses AAV5 capsid vectors and riboswitch technology to deliver gene therapies, aiming for safer and more controlled treatments compared to earlier approaches. Financially, MGTX has a strong cash position bolstered by a $200mn deal with Hologen, providing a substantial runway for continued development.
Read More
About MeiraGTx Holdings plc (MGTX)
- IPO Date 2018-06-08
- Website https://www.meiragtx.com
- Industry Biotechnology
- CEO Dr. Alexandria Forbes Ph.D.
- Employees 375